Sunshine Biopharma
Commercializer of Canadian generic medicines with early-stage oncology and antiviral research.
Something off on this page? Send us feedback.
Profile
Sells Canadian generic prescription drugs through Nora Pharma across pharmacy channels under licensed and distribution arrangements. A smaller proprietary pipeline targets liver cancer and SARS-coronavirus infections, while commercial operations depend on Health Canada approvals, provincial drug policies, and third-party suppliers.
Commercializes generic prescription drugs in Canada through Nora Pharma, using in-licensed, cross-licensed, and distribution arrangements. Products cover oncology, cardiovascular medicine, central-nervous-system disorders, anti-infectives, urology, diabetes, allergy, and women's health, and reach pharmacies, distributors, wholesalers, and direct pharmacy customers. Quebec is the principal market, with smaller exposure to Ontario, Alberta, and British Columbia.
Maintains smaller proprietary research programs: K1.1, an mRNA-lipid-nanoparticle liver-cancer candidate, and SBFM-PL4, a small-molecule protease inhibitor for SARS-coronavirus infections. Both remain at animal testing and had no regulatory filings as of the annual report. Canadian sales depend on Health Canada approvals, provincial pricing and formularies, and overseas suppliers that manufacture nearly all Nora products.
Company facts
Key statistics
Year to date −91.1% · Average volume (30d) 969.2K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$1.15 | −$1.15 | 0.0% | $9.3M | $9.3M | −0.4% | −0.83% |
| Aug 11, 2026Q2 FY26 | −$1.20 | — | — | $8.7M | −$9.4M | −208.2% | −1.63% |
| May 13, 2026Q1 FY26 | −$2.50 | −$2.50 | 0.0% | $8.1M | $8.1M | 0.0% | −28.94% |
| Apr 3, 2026Q4 FY25 | −$2.70 | −$3.00 | −11.1% | $10.0M | $8.6M | −14.0% | +11.54% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $8.9M | $9.4M | $9.4M | $8.6M | $8.1M | $9.3M | |
| Gross profit | $2.7M | $3.4M | $3.1M | $2.9M | $2.1M | $2.4M | |
| Operating income | −$1.3M | −$992.8K | −$532.0K | −$1.7M | −$1.4M | −$1.6M | |
| Net income | −$1.2M | −$1.8M | −$883.8K | −$2.1M | −$1.2M | −$1.6M | |
| Diluted EPS | −$4.40 | −$78.00 | −$1.90 | −$4.60 | −$2.50 | −$1.15 | |
| Gross margin | 30.7% | 36.4% | 32.6% | 34.2% | 26.0% | 26.2% | |
| Operating margin | -14.6% | -10.6% | -5.6% | -19.3% | -17.3% | -17.4% |
Fiscal years (4-quarter sums)FY21 $228.4K · FY22 $4.3M · FY23 $24.1M · FY24 $34.9M · FY25 $36.3M
Balance sheet, Jun 30, 2026Cash & short-term investments $13.7M · Total debt $678.3K · Total assets $33.6M · Shareholders' equity $27.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 2.38M · Float 498.2K · 21.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Alta Partners LLC | 200.0K | 8.60% | 13G | Jul 8, 2026 |
| David Natan · director | 68.3K | 2.87% | Form 4 | Aug 11, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Teva (ADR)
Large Canadian generic and biosimilar portfolio contests pharmacy access.
- Viatris
Broad Canadian generics compete across major prescription therapies.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sunshine Biopharma | $1.14 | 0.00% | $2.7M | — | — | 0.1 | −1.6% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Viatris | $16.30 | −0.23% | $19.03B | — | 6.4 | 1.3 | +4.9% |
| Median | 60.7 | 9.6 | 1.9 | +2.0% |